Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 8, 2007, Pages 913-924

  Tey, Siok Keen ^a   Dotti, Gianpietro ^a   Rooney, Cliona M ^a   Heslop, Helen E ^a   Brenner, Malcolm K ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Gene therapy; Graft versus host disease; Haploidentical; Hematopoietic stem cell transplantation; Immunotherapy; T lymphocyte

Indexed keywords

CASPASE 9; CD19 ANTIGEN; IMMUNOTOXIN; RETROVIRUS VECTOR;

ALLOIMMUNITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DONOR; DOWN REGULATION; FEASIBILITY STUDY; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; SAFETY; STEM CELL TRANSPLANTATION; SUICIDE GENE THERAPY; T CELL DEPLETION; TRANSGENE; UPREGULATION;

APOPTOSIS; CASPASE 9; FEASIBILITY STUDIES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 34447310075     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.04.005     Document Type: Article

References (37)

1. Kolb H., Schattenberg A., Goldman J., et al., European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 (1995) 2041-2050
2. Papadopoulos E.B., Ladanyi M., Emanuel D., et al. Infusions of donor leukocytes to treat Epstein-Barr Virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330 (1994) 1185-1191
3. Drobyski W.R., Hessner M.J., Klein J.P., et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 94 (1999) 434-441
4. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
5. Lang P., Greil J., Bader P., et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Molecules Dis 33 (2004) 281-287
6. Lewalle P., Triffet A., Delforge A., et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 31 (2003) 39-44
7. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108 (2006) 1797-1808
8. Andre-Schmutz I., Le Deist F., Hacein-Bey-Abina S., et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 360 (2002) 130-137
9. Solomon S.R., Mielke S., Savani B.N., et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106 (2005) 1123-1129
10. Molldrem J.J., Lee P.P., Wang C., Champlin R.E., and Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59 (1999) 2675-2681
11. Rezvani K., Grube M., Brenchley J.M., et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102 (2003) 2892-2900
12. Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100 (2002) 397-405
13. Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997) 1719-1724
14. Tiberghien P., Ferrand C., Lioure B., et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97 (2001) 63-72
15. Bonini C., Ciceri F., Stanghellini M.T.L., et al. Rapid and wide immunereconstitution obtained with HSV-TK engineered donor lymphocyte add-backs permits long-term survival after haplo-HSCT. ASH Annu Meet Abstr 108 (2006) 307
16. Berger C., Flowers M.E., Warren E.H., and Riddell S.R. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107 (2006) 2294-2302
17. Garin M.I., Garrett E., Tiberghien P., et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97 (2001) 122-129
18. Straathof K.C., Pule M.A., Yotnda P., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 105 (2005) 4247-4254
19. Thomis D.C., Marktel S., Bonini C., et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97 (2001) 1249-1257
20. Amrolia P.J., Muccioli-Casadei G., Yvon E., et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102 (2003) 2292-2299
21. Ghetie V., Thorpe P., Ghetie M.A., Knowles P., Uhr J.W., and Vitetta E.S. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J Immunol Methods 142 (1991) 223-230
22. Clackson T., Yang W., Rozamus L.W., et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 95 (1998) 10437-10442
23. Donnelly M.L.L., Hughes L.E., Luke G., et al. The "cleavage" activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring "2A-like" sequences. J Gen Virol 82 (2001) 1027-1041
24. Zhou L.J., Ord D.C., Hughes A.L., and Tedder T.F. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain. J Immunol 147 (1991) 1424-1432
25. Fujimoto M., Poe J.C., Inaoki M., and Tedder T.F. CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol 10 (1998) 267-277
26. Sauce D., Bodinier M., Garin M., et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 99 (2002) 1165-1173
27. Li Z., Dullmann J., Schiedlmeier B., et al. Murine leukemia induced by retroviral gene marking. Science 296 (2002) 497
28. Bonini C., Grez M., Traversari C., et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9 (2003) 367-369
29. Rettig M.P., Ritchey J.K., Meyerrose T.E., Haug J.S., and DiPersio J.F. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Mol Ther 8 (2003) 29-41
30. Fehse B., Richters A., Putimtseva-Scharf K., et al. CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol Ther 1 (2000) 448-456
31. Lanza F., Healy L., and Sutherland D.R. Structural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents 15 (2001) 1-13
32. Tiberghien P., Reynolds C., Keller J., et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?. Blood 84 (1994) 1333-1341
33. Verzeletti S., Bonini C., Marktel S., et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 9 (1998) 2243-2251
34. Iuliucci J., Oliver S., Morley S., et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41 (2001) 870-879
35. Bondanza A., Valtolina V., Magnani Z., et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 107 (2006) 1828-1836
36. Berger C., Blau C.A., Clackson T., Riddell S.R., and Heimfeld S. CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood 101 (2003) 476-484
37. Mesel-Lemoine M., Cherai M., Le Gouvello S., et al. Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. Blood 107 (2006) 381-388